Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBVZND)

Drug Name
ONYX-015 Drug Info
Synonyms Dl1520; E1B-deleted adenovirus (cancer), ONYX
Indication
Disease Entry ICD 11 Status REF
Head and neck cancer 2D42 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMBVZND

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cellular tumor antigen p53 (TP53) TT7SBF5 P53_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Cellular tumor antigen p53 (TP53) DTT TP53 5.257 4.938 5.396 5.626
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Head and neck cancer
ICD Disease Classification 2D42
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cellular tumor antigen p53 (TP53) DTT TP53 7.01E-01 0.06 0.09
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00006106) ONYX-015 With Cisplatin and Fluorouracil in Treating Patients With Advanced Head and Neck Cancer. U.S. National Institutes of Health.
2 Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell. 2004 Dec;6(6):611-23.